Addition of etoposide to cyclophosphamide, doxorubicin and vincristine for remission induction and survival in patients with small cell lung cancer

A. A. Messeih, J. M. Schweitzer, A. Lipton, H. A. Harvey, M. A. Simmonds, J. A. Stryker, J. A. Ricci, S. L. Hoffman, R. J. Gottleib, R. H. Dixon

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

A total of 116 patients with small cell lung cancer were randomized to receive either: cyclophosphamide, 750 mg/m2, doxorubicin, 50 mg/m2, and vincristine, 2 mg iv (Regimen A), or the same drugs plus etoposide, 100 mg/m2 iv daily for 2 days (Regimen B) every 3 weeks. Complete responders received whole-brain radiation therapy. The overall response rates were 50% for Regimen A and 65% for Regimen B (P < 0.05). The complete response rates were 18% for Regimen A and 44% for Regimen B (P < 0.01). For patients with limited disease, the complete responders were 35% on Regimen A and 52% on Regimen B (P = 0.26); for those with extensive disease, the complete responders were 0% on Regimen A and 35% on Regimen B (P = 0.002). The median survival for complete responders was 17 months on Regimen A and 20 months on Regimen B. The difference is not statistically significant. Toxicity was tolerable for both groups; however, it was greater for the etoposide arm. We conclude that although etoposide improves the overall response rates in patients with small cell lung cancer, especially those with extensive disease, the addition of this drug does not lead to improved survival.

Original languageEnglish (US)
Pages (from-to)61-66
Number of pages6
JournalCancer Treatment Reports
Volume71
Issue number1
StatePublished - Mar 25 1987

Fingerprint

Remission Induction
Small Cell Lung Carcinoma
Vincristine
Etoposide
Doxorubicin
Cyclophosphamide
Survival
Pharmaceutical Preparations
Regimen B
Radiotherapy
Brain

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Messeih, A. A. ; Schweitzer, J. M. ; Lipton, A. ; Harvey, H. A. ; Simmonds, M. A. ; Stryker, J. A. ; Ricci, J. A. ; Hoffman, S. L. ; Gottleib, R. J. ; Dixon, R. H. / Addition of etoposide to cyclophosphamide, doxorubicin and vincristine for remission induction and survival in patients with small cell lung cancer. In: Cancer Treatment Reports. 1987 ; Vol. 71, No. 1. pp. 61-66.
@article{751ccd3df0e441eea40707313655bc47,
title = "Addition of etoposide to cyclophosphamide, doxorubicin and vincristine for remission induction and survival in patients with small cell lung cancer",
abstract = "A total of 116 patients with small cell lung cancer were randomized to receive either: cyclophosphamide, 750 mg/m2, doxorubicin, 50 mg/m2, and vincristine, 2 mg iv (Regimen A), or the same drugs plus etoposide, 100 mg/m2 iv daily for 2 days (Regimen B) every 3 weeks. Complete responders received whole-brain radiation therapy. The overall response rates were 50{\%} for Regimen A and 65{\%} for Regimen B (P < 0.05). The complete response rates were 18{\%} for Regimen A and 44{\%} for Regimen B (P < 0.01). For patients with limited disease, the complete responders were 35{\%} on Regimen A and 52{\%} on Regimen B (P = 0.26); for those with extensive disease, the complete responders were 0{\%} on Regimen A and 35{\%} on Regimen B (P = 0.002). The median survival for complete responders was 17 months on Regimen A and 20 months on Regimen B. The difference is not statistically significant. Toxicity was tolerable for both groups; however, it was greater for the etoposide arm. We conclude that although etoposide improves the overall response rates in patients with small cell lung cancer, especially those with extensive disease, the addition of this drug does not lead to improved survival.",
author = "Messeih, {A. A.} and Schweitzer, {J. M.} and A. Lipton and Harvey, {H. A.} and Simmonds, {M. A.} and Stryker, {J. A.} and Ricci, {J. A.} and Hoffman, {S. L.} and Gottleib, {R. J.} and Dixon, {R. H.}",
year = "1987",
month = "3",
day = "25",
language = "English (US)",
volume = "71",
pages = "61--66",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "1",

}

Messeih, AA, Schweitzer, JM, Lipton, A, Harvey, HA, Simmonds, MA, Stryker, JA, Ricci, JA, Hoffman, SL, Gottleib, RJ & Dixon, RH 1987, 'Addition of etoposide to cyclophosphamide, doxorubicin and vincristine for remission induction and survival in patients with small cell lung cancer', Cancer Treatment Reports, vol. 71, no. 1, pp. 61-66.

Addition of etoposide to cyclophosphamide, doxorubicin and vincristine for remission induction and survival in patients with small cell lung cancer. / Messeih, A. A.; Schweitzer, J. M.; Lipton, A.; Harvey, H. A.; Simmonds, M. A.; Stryker, J. A.; Ricci, J. A.; Hoffman, S. L.; Gottleib, R. J.; Dixon, R. H.

In: Cancer Treatment Reports, Vol. 71, No. 1, 25.03.1987, p. 61-66.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Addition of etoposide to cyclophosphamide, doxorubicin and vincristine for remission induction and survival in patients with small cell lung cancer

AU - Messeih, A. A.

AU - Schweitzer, J. M.

AU - Lipton, A.

AU - Harvey, H. A.

AU - Simmonds, M. A.

AU - Stryker, J. A.

AU - Ricci, J. A.

AU - Hoffman, S. L.

AU - Gottleib, R. J.

AU - Dixon, R. H.

PY - 1987/3/25

Y1 - 1987/3/25

N2 - A total of 116 patients with small cell lung cancer were randomized to receive either: cyclophosphamide, 750 mg/m2, doxorubicin, 50 mg/m2, and vincristine, 2 mg iv (Regimen A), or the same drugs plus etoposide, 100 mg/m2 iv daily for 2 days (Regimen B) every 3 weeks. Complete responders received whole-brain radiation therapy. The overall response rates were 50% for Regimen A and 65% for Regimen B (P < 0.05). The complete response rates were 18% for Regimen A and 44% for Regimen B (P < 0.01). For patients with limited disease, the complete responders were 35% on Regimen A and 52% on Regimen B (P = 0.26); for those with extensive disease, the complete responders were 0% on Regimen A and 35% on Regimen B (P = 0.002). The median survival for complete responders was 17 months on Regimen A and 20 months on Regimen B. The difference is not statistically significant. Toxicity was tolerable for both groups; however, it was greater for the etoposide arm. We conclude that although etoposide improves the overall response rates in patients with small cell lung cancer, especially those with extensive disease, the addition of this drug does not lead to improved survival.

AB - A total of 116 patients with small cell lung cancer were randomized to receive either: cyclophosphamide, 750 mg/m2, doxorubicin, 50 mg/m2, and vincristine, 2 mg iv (Regimen A), or the same drugs plus etoposide, 100 mg/m2 iv daily for 2 days (Regimen B) every 3 weeks. Complete responders received whole-brain radiation therapy. The overall response rates were 50% for Regimen A and 65% for Regimen B (P < 0.05). The complete response rates were 18% for Regimen A and 44% for Regimen B (P < 0.01). For patients with limited disease, the complete responders were 35% on Regimen A and 52% on Regimen B (P = 0.26); for those with extensive disease, the complete responders were 0% on Regimen A and 35% on Regimen B (P = 0.002). The median survival for complete responders was 17 months on Regimen A and 20 months on Regimen B. The difference is not statistically significant. Toxicity was tolerable for both groups; however, it was greater for the etoposide arm. We conclude that although etoposide improves the overall response rates in patients with small cell lung cancer, especially those with extensive disease, the addition of this drug does not lead to improved survival.

UR - http://www.scopus.com/inward/record.url?scp=0023129757&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023129757&partnerID=8YFLogxK

M3 - Article

C2 - 3024828

AN - SCOPUS:0023129757

VL - 71

SP - 61

EP - 66

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 1

ER -